

Supplemental Material




Figure S1. Representative tracings from LabChart Chart View of Animal 7 that was excluded due to arrhythmia.

	PV-loop	Echocardiography	MRI
HR (bpm)	202 ± 17	257 ± 17	230 ± 22
ESV (μl)	99 ± 23	87 ± 20	368 ± 21*
EDV (μl)	325 ± 31	272 ± 30	1000 ± 62*
SV (μl)	225 ± 31	185 ± 11	631 ± 53*
EF(%)	70 ± 7	69 ± 3	63 ± 2
CO (ml/min)	45 ± 7	47 ± 2	150 ± 23*

Table S1. Functional hemodynamic data acquired via PV-loop, Echocardiography and MRI of the same 5 animals.

HR = Heart Rate, ESV = End Systolic Volume, EDV = End Diastolic Volume, SV = Stroke Volume, EF = Ejection Fraction, CO = Cardiac Output

*=MRI data significantly different to PV-loop and Echocardiography ($p<0.05$) Data shown as mean ± SEM (n=5)

	Advantages	Disadvantages
Marmoset	<ul style="list-style-type: none"> - close phylogenetic relationship to humans [62, 63] - relatively rapid reproduction with twin birth [7, 31, 64, 65]; twins exhibit bone marrow chimerism [7, 31, 66-68] - commonly used for various biomedical research fields [7, 8, 69] - relatively easy to handle [7, 8] - least expensive NHP [31] with low zoonotic hazard [8, 31] - used for CV research since the 80s [45, 70-72] - similarities in heart anatomy and relative heart weight [19, 21] - heart size more suitable compared to rats for angiographic investigation [70] - spontaneous development of heart fibrosis, inflammatory cell infiltration and myocardial degeneration [41, 42] - similar age-related changes in microvasculature [73] - mean myocyte volume similar to man [40] - similar age-related changes in cardiovascular system [22, 43], immunology [17] as well as neurological and motor system [74-77] making it suitable for aging research [11, 15, 62, 63, 78] - spontaneous or induced models of obesity and diabetes [14] - similar lipoprotein profile [79-81] - good model to study renin-angiotensin system [82, 83] - possibility for transgenic applications [63, 84] -)similar ECG values(<ul style="list-style-type: none"> - some aspects of the cardiovascular system have been studied (see Advantages), but heart function has never been comprehensively characterized - rhesus macaques closer resemble the human situation [85] - few researchers have experience with marmosets - lower availability than small rodents - relatively expensive/ complicated husbandry and breeding compared to rodents [38, 86] - longer life cycle than rodents - slight differences in cardiac anatomy [37] and myocyte structure [40] compared to human - ethical considerations [36] - heart rate differs from human - difficulties in genetic modification [38] - limited availability of cross-reacting antibodies [39]
Pig	<ul style="list-style-type: none"> - highest analogy of heart and blood vessel sizes [87] - induced lesions more similar to human disease [88] - collateralization enables total infarct by occluding left anterior descending artery [87] - similarity in physiology, metabolism, genomics and proteomics to human [89, 90] 	<ul style="list-style-type: none"> - high cost compared to rodents[38, 88] - difficult handling [88] - few genomic tools [88] - most antibodies for human are not effective in pigs [90]

- | | | |
|--------------|--|---|
| Dog | <ul style="list-style-type: none"> - availability of various heart disease models and genetically established cardiomyopathy [89] - valid for restenosis studies [88] - genetically modified established model for human atherosclerosis [38] - non-invasive techniques for heart catheterization [91] - availability of monitoring systems in chronic models [91] - availability of imaging-based study techniques [91] <hr/> <ul style="list-style-type: none"> - docility and cognitive performance allow non-invasive and non-sedated assessments [92] - shared genetic evolution with humans [92, 93] - left ventricular function and volume similar to human [94] - myosin heavy chain distribution similar to human [94] - comparable electrophysiology [95] - cardiac proteome similar to human [90] - established disease models [96-98] - genetic modifications possible [92] - availability of monitoring systems in chronic models [91] - availability of imaging-based study techniques [91] - naturally occurring cardiomyopathies (summarized in [99]) <hr/> | <ul style="list-style-type: none"> - variation in coronary artery supply compared to humans as well as between individual dogs results in a complicated surgery setting for MI [87, 100, 101] - differences in heart anatomy [102] - relatively costly/ complicated housing and breeding [38, 90, 94] - most antibodies for human are not effective in dogs [90] - genetic modification not as easy as in small rodents [38, 103] - complicated operation [38] - ethical considerations due to companion animal status (in Europe) <hr/> |
| Mouse | <ul style="list-style-type: none"> - large experience [38, 88] - well-known genome, relative ease of genome manipulation [88] - low cost [88, 94] - short reproductive cycle [38, 88, 91, 94] allows for studies over short time period - useful for noninvasive imaging [88] - rapid development of atherosclerotic plaques in transgenic mice under specific diet [88] - standardized feeding and housing conditions with low variability [38] <hr/> | <ul style="list-style-type: none"> - only partial resemblance to humans [88] - heart rate differs significantly from humans [94, 104] - cardiac metabolism differs from human [105] - action potential differs to the human one [94] - different ratio of α- and β-myosin heavy chains [94] - atherosclerosis does not occur spontaneously in mice [106], more atherosclerotic than atherothrombosis model [88] - very high level of blood lipids [88] <hr/> |
| Rat | <ul style="list-style-type: none"> - easy to handle, available, low cost [88] - short reproductive cycle [91] <hr/> | <ul style="list-style-type: none"> - heart rate differs significantly from humans - do not develop atheroma [88] |

	<ul style="list-style-type: none"> - established model of choice for decades in cardiovascular research [107] - useful for restenosis analysis [88] 	<ul style="list-style-type: none"> - modification of hemodynamic conditions in open-thorax models [91]
Rabbit	<ul style="list-style-type: none"> - established disease models [108, 109] - inexpensive, easily available [88, 110] - easy to handle, medium size [88] - short reproductive cycle [111] - mimics alteration of myocardial function observed in end stage failing human myocard [94] - development of fibroatheroma lesion in atherosclerosis model [88] - useful for restenosis models [88] - WHHLMI strain develops myocardial infarction spontaneously [109] 	<ul style="list-style-type: none"> - heart rate differs from humans [104] - few genomic tools [88] - differences in cardiac metabolism [103] - need for high blood cholesterol levels for development of atherosclerosis [88]

Table S2. Selected advantages and disadvantages of different animal models relevant for cardiovascular research.

References

62. Fischer, K.E.; Austad, S.N. The development of small primate models for aging research. *ILAR J.* 2011, **52**, 78–88. <https://doi.org/10.1093/ilar.52.1.78>.
63. Mattison, J.A.; Vaughan, K.L. An overview of nonhuman primates in aging research. *Exp. Gerontol.* 2017, **94**, 41–45. <https://doi.org/10.1016/j.exger.2016.12.005>.
64. Abbott, D.H.; Hearn, J.P. Physical, hormonal and behavioural aspects of sexual development in the marmoset monkey, *Callithrix jacchus*. *J. Reprod. Fertil.* 1978, **53**, 155–166. <https://doi.org/10.1530/jrf.0.0530155>.
65. Tardif, S.D.; Smucny, D.A.; Abbott, D.H.; Mansfield, K.; Schultz-Darken, N.; Yamamoto, M.E. Reproduction in captive common marmosets (*Callithrix jacchus*). *Comp. Med.* 2003, **53**, 364–368.
66. Benirschke, K.; Anderson, J.M.; Brownhill, L.E. Marrow Chimerism in Marmosets. *Science* 1962, **138**, 513–515. <https://doi.org/10.1126/science.138.3539.513>.
67. Benirschke, K.; Brownhill, L.E. Further observations on marrow chimerism in marmosets. *Cytogenetics* 1962, **1**, 245–257. <https://doi.org/10.1159/000129734>.
68. Silva, M.O.M.; Armada, J.L.A.; Verona, C.E.S.; Heliodoro, G.; Nogueira, D.M. Cytogenetic and Molecular Genetic Analysis of Chimerism in Marmosets (*Callithrix*: Primates). *An. Acad. Bras. Cienc.* 2017, **89**, 2793–2804. <https://doi.org/10.1590/0001-3765201720170484>.
69. Greenough, T.C.; Carville, A.; Coderre, J.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Mansfield, K. Pneumonitis and multi-organ system disease in common marmosets (*Callithrix jacchus*) infected with the severe acute respiratory syndrome-associated coronavirus. *Am. J. Pathol.* 2005, **167**, 455–463. [https://doi.org/10.1016/s0002-9440\(10\)62989-6](https://doi.org/10.1016/s0002-9440(10)62989-6).
70. Charnock, J.S.; McLennan, P.L.; McIntosh, G.H.; Barnden, L.R.; Buttfield, I.H. Radionuclide angiographic study of the influence of dietary lipid supplements on cardiac function in the marmoset (*Callithrix jacchus*). *Cardiovasc. Res.* 1987, **21**, 369–376. <https://doi.org/10.1093/cvr/21.5.369>.
71. McMurchie, E.J.; Patten, G.S.; McLennan, P.L.; Charnock, J.S.; Nestel, P.J. The influence of dietary lipid supplementation on cardiac beta-adrenergic receptor adenylate cyclase activity in the marmoset monkey. *Biochim. Biophys. Acta* 1988, **937**, 347–358. [https://doi.org/10.1016/0005-2736\(88\)90257-x](https://doi.org/10.1016/0005-2736(88)90257-x).

72. McMurchie, E.J.; Patten, G.S.; McLennan, P.L.; Charnock, J.S. A comparison of the properties of the cardiac beta-adrenergic receptor adenylyl cyclase system in the rat and the marmoset monkey. *Comp. Biochem. Physiol. B* **1987**, *88*, 989–998. [https://doi.org/10.1016/0305-0491\(87\)90275-6](https://doi.org/10.1016/0305-0491(87)90275-6).
73. Sabin, S.S.; Bernick, S.; Ballard, K.W. Histochemical characterization of the aging microvasculature in the human and other mammalian and non-mammalian vertebrates by the periodic acid-Schiff reaction. *Mech. Ageing Dev.* **1992**, *63*, 183–192. [https://doi.org/10.1016/0047-6374\(92\)90064-k](https://doi.org/10.1016/0047-6374(92)90064-k).
74. Geula, C.; Nagykery, N.; Wu, C.K. Amyloid-beta deposits in the cerebral cortex of the aged common marmoset (*Callithrix jacchus*): Incidence and chemical composition. *Acta Neuropathol.* **2002**, *103*, 48–58. <https://doi.org/10.1007/s004010100429>.
75. Berkovitz, B.K.; Pacy, J. Age changes in the cells of the intra-articular disc of the temporomandibular joints of rats and marmosets. *Arch. Oral Biol.* **2000**, *45*, 987–995. [https://doi.org/10.1016/s0003-9969\(00\)00067-4](https://doi.org/10.1016/s0003-9969(00)00067-4).
76. Harada, T.; Tokuriki, M.; Tanioka, Y. Age-related changes in the brainstem auditory evoked potentials of the marmoset. *Heart Res.* **1999**, *128*, 119–124. [https://doi.org/10.1016/s0378-5955\(98\)00201-9](https://doi.org/10.1016/s0378-5955(98)00201-9).
77. Black, A.; Lane, M.A. Nonhuman primate models of skeletal and reproductive aging. *Gerontology* **2002**, *48*, 72–80. <https://doi.org/10.1159/000048930>.
78. Ross, C.N.; Salmon, A.B. Aging research using the common marmoset: Focus on aging interventions. *Nutr. Healthy Aging* **2019**, *5*, 97–109. <https://doi.org/10.3233/nha-180046>.
79. Crook, D.; Weisgraber, K.H.; Boyles, J.K.; Mahley, R.W. Isolation and characterization of plasma lipoproteins of common marmoset monkey. Comparison of effects of control and atherogenic diets. *Arteriosclerosis* **1990**, *10*, 633–647. <https://doi.org/10.1161/01.atv.10.4.633>.
80. Abbey, M.; Clifton, P.M.; McMurchie, E.J.; McIntosh, G.H.; Nestel, P.J. Effect of a high fat/cholesterol diet with or without eicosapentaenoic acid on plasma lipids, lipoproteins and lipid transfer protein activity in the marmoset. *Atherosclerosis* **1990**, *81*, 163–174. [https://doi.org/10.1016/0021-9150\(90\)90063-o](https://doi.org/10.1016/0021-9150(90)90063-o).
81. Lima, V.L.; Sena, V.L.; Stewart, B.; Owen, J.S.; Dolphin, P.J. An evaluation of the marmoset *Callithrix jacchus* (saguí) as an experimental model for the dyslipoproteinemia of human Schistosomiasis mansoni. *Biochim. Biophys. Acta* **1998**, *1393*, 235–243. [https://doi.org/10.1016/s0005-2760\(98\)00076-9](https://doi.org/10.1016/s0005-2760(98)00076-9).
82. Michel, J.B.; Wood, J.; Hofbauer, K.; Corvol, P.; Menard, J. Blood pressure effects of renin inhibition by human renin antiserum in normotensive marmosets. *Am. J. Physiol.* **1984**, *246*, F309–F316. <https://doi.org/10.1152/ajrenal.1984.246.3.F309>.
83. Hiruma, M.; Kim, S.; Ikemoto, F.; Murakami, K.; Yamamoto, K. Fate of recombinant human renin administered exogenously to anesthetized monkeys. *Hypertension* **1988**, *12*, 317–323. <https://doi.org/10.1161/01.hyp.12.3.317>.
84. Drummer, C.; Vogt, E.J.; Heistermann, M.; Roshani, B.; Becker, T.; Mätz-Rensing, K.; Kues, W.A.; Kügler, S.; Behr, R. Generation and Breeding of EGFP-Transgenic Marmoset Monkeys: Cell Chimerism and Implications for Disease Modeling. *Cells* **2021**, *10*, 505. <https://doi.org/10.3390/cells10030505>.
85. Preuss, T.M. Critique of Pure Marmoset. *Brain Behav. Evol.* **2019**, *93*, 92–107. <https://doi.org/10.1159/000500500>.
86. Holtze, S.; Gorshkova, E.; Braude, S.; Cellerino, A.; Dammann, P.; Hildebrandt, T.B.; Hoeflich, A.; Hoffmann, S.; Koch, P.; Terzibasi Tozzini, E.; et al. Alternative Animal Models of Aging Research. *Front. Mol. Biosci.* **2021**, *8*, 660959. <https://doi.org/10.3389/fmolb.2021.660959>.
87. Swindle, M.M.; Makin, A.; Herron, A.J.; Clubb, F.J., Jr.; Frazier, K.S. Swine as models in biomedical research and toxicology testing. *Vet. Pathol.* **2012**, *49*, 344–356. <https://doi.org/10.1177/0300985811402846>.
88. Zaragoza, C.; Gomez-Guerrero, C.; Martin-Ventura, J.L.; Blanco-Colio, L.; Lavin, B.; Mallavia, B.; Tarin, C.; Mas, S.; Ortiz, A.; Egido, J. Animal models of cardiovascular diseases. *J. Biomed. Biotechnol.* **2011**, *2011*, 497841. <https://doi.org/10.1155/2011/497841>.
89. Hiroaki, O.; Kozue, M.; Hidetoshi, M. Large Animal Models in Cardiovascular Research. In *Animal Models and Experimental Research in Medicine*; Mahmut, K., Volkan, G., Abdulsamed, K., Eds.; IntechOpen: Rijeka, Croatia, 2022; p. Ch. 11.
90. Kooij, V.; Venkatraman, V.; Tra, J.; Kirk, J.A.; Rowell, J.; Blice-Baum, A.; Cammarato, A.; Van Eyk, J.E. Sizing up models of heart failure: Proteomics from flies to humans. *Proteom. Clin. Appl.* **2014**, *8*, 653–664. <https://doi.org/10.1002/prca.201300123>.
91. Chorro, F.J.; Such-Belenguer, L.; López-Merino, V. Animal Models of Cardiovascular Disease. *Rev. Española Cardiol. (Engl. Ed.)* **2009**, *62*, 69–84. [https://doi.org/10.1016/S1885-5857\(09\)71516-6](https://doi.org/10.1016/S1885-5857(09)71516-6).

92. Barthélémy, I.; Hitte, C.; Tiret, L. The Dog Model in the Spotlight: Legacy of a Trustful Cooperation. *J. Neuromuscul. Dis.* **2019**, *6*, 421–451. <https://doi.org/10.3233/jnd-190394>.
93. Wang, G.D.; Zhai, W.; Yang, H.C.; Fan, R.X.; Cao, X.; Zhong, L.; Wang, L.; Liu, F.; Wu, H.; Cheng, L.G.; et al. The genomics of selection in dogs and the parallel evolution between dogs and humans. *Nat. Commun.* **2013**, *4*, 1860. <https://doi.org/10.1038/ncomms2814>.
94. Hasenfuss, G. Animal models of human cardiovascular disease, heart failure and hypertrophy. *Cardiovasc. Res.* **1998**, *39*, 60–76. [https://doi.org/10.1016/S0008-6363\(98\)00110-2](https://doi.org/10.1016/S0008-6363(98)00110-2).
95. Kaese, S.; Frommeyer, G.; Verheule, S.; van Loon, G.; Gehrmann, J.; Breithardt, G.; Eckardt, L. The ECG in cardiovascular-relevant animal models of electrophysiology. *Herzschriftmacherther. Elektrophysiolog.* **2013**, *24*, 84–91. <https://doi.org/10.1007/s00399-013-0260-z>.
96. Lavine, S.J. Effect of changes in contractility on the index of myocardial performance in the dysfunctional left ventricle. *Cardiovasc. Ultrasound* **2006**, *4*, 45. <https://doi.org/10.1186/1476-7120-4-45>.
97. Loen, V.; Vos, M.A.; van der Heyden, M.A.G. The canine chronic atrioventricular block model in cardiovascular preclinical drug research. *Br. J. Pharmacol.* **2022**, *179*, 859–881. <https://doi.org/10.1111/bph.15436>.
98. Powers, J.C.; Recchia, F. Canine Model of Pacing-Induced Heart Failure. *Methods Mol. Biol.* **2018**, *1816*, 309–325. https://doi.org/10.1007/978-1-4939-8597-5_24.
99. Duncker, D.J.; Bakkers, J.; Brundel, B.J.; Robbins, J.; Tardiff, J.C.; Carrier, L. Animal and in silico models for the study of sarcomeric cardiomyopathies. *Cardiovasc. Res.* **2015**, *105*, 439–448. <https://doi.org/10.1093/cvr/cvv006>.
100. Lowe, J.E.; Reimer, K.A.; Jennings, R.B. Experimental infarct size as a function of the amount of myocardium at risk. *Am. J. Pathol.* **1978**, *90*, 363–379.
101. Khan, M.S.; Smego, D.; Ishidoya, Y.; Hirahara, A.M.; Offei, E.; Ruiz Castillo, M.S.; Gharbia, O.; Li, H.; Palatinus, J.A.; Krueger, L.; et al. A canine model of chronic ischemic heart failure. *Am. J. Physiol. Heart Circ. Physiol.* **2023**, *324*, H751–H761. <https://doi.org/10.1152/ajpheart.00647.2022>.
102. Chevènement, O.; Borenstein, N.; Kieval, R.; Fiette, L.; Aujard, F. Animal model considerations to evaluate prosthetic tricuspid valve implants. *Ann. Anat.* **2021**, *234*, 151625. <https://doi.org/10.1016/j.aanat.2020.151625>.
103. Milani-Nejad, N.; Janssen, P.M. Small and large animal models in cardiac contraction research: Advantages and disadvantages. *Pharmacol. Ther.* **2014**, *141*, 235–249. <https://doi.org/10.1016/j.pharmthera.2013.10.007>.
104. Hornyik, T.; Rieder, M.; Castiglione, A.; Major, P.; Bacsko, I.; Brunner, M.; Koren, G.; Odening, K.E. Transgenic rabbit models for cardiac disease research. *Br. J. Pharmacol.* **2022**, *179*, 938–957. <https://doi.org/10.1111/bph.15484>.
105. Ginis, I.; Luo, Y.; Miura, T.; Thies, S.; Brandenberger, R.; Gerecht-Nir, S.; Amit, M.; Hoke, A.; Carpenter, M.K.; Itskovitz-Eldor, J.; et al. Differences between human and mouse embryonic stem cells. *Dev. Biol.* **2004**, *269*, 360–380. <https://doi.org/10.1016/j.ydbio.2003.12.034>.
106. Emini Veseli, B.; Perrotta, P.; De Meyer, G.R.A.; Roth, L.; Van der Donckt, C.; Martinet, W.; De Meyer, G.R.Y. Animal models of atherosclerosis. *Eur. J. Pharmacol.* **2017**, *816*, 3–13. <https://doi.org/10.1016/j.ejphar.2017.05.010>.
107. Bader, M. Rat Models of Cardiovascular Diseases. In *Rat Genomics: Methods and Protocols*; Anegón, I., Ed.; Humana Press: Totowa, NJ, USA, 2010; pp. 403–414. https://doi.org/10.1007/978-1-60327-389-3_27.
108. González, G.E.; Seropian, I.M.; Krieger, M.L.; Palleiro, J.; Lopez Verrilli, M.A.; Gironacci, M.M.; Cavallero, S.; Wilensky, L.; Tomasi, V.H.; Gelpi, R.J.; et al. Effect of early versus late AT(1) receptor blockade with losartan on postmyocardial infarction ventricular remodeling in rabbits. *Am. J. Physiol. Heart Circ. Physiol.* **2009**, *297*, H375–H386. <https://doi.org/10.1152/ajpheart.00498.2007>.
109. Shiomi, M.; Ito, T.; Yamada, S.; Kawashima, S.; Fan, J. Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). *Arterioscler. Thromb. Vasc. Biol.* **2003**, *23*, 1239–1244. <https://doi.org/10.1161/01.ATV.0000075947.28567.50>.
110. Chobanian, A.V.; Arquilla, E.R.; Clarkson, T.B.; Eder, H.A.; Howard, C.F., Jr.; Regan, T.J.; Williamson, J.R. Cardiovascular complications. *Diabetes* **1982**, *31*, 54–64. <https://doi.org/10.2337/diab.31.1.s54>.
111. Calasans-Maia, M.D.; Monteiro, M.L.; Ascoli, F.O.; Granjeiro, J.M. The rabbit as an animal model for experimental surgery. *Acta Cir. Bras.* **2009**, *24*, 325–328. <https://doi.org/10.1590/s0102-86502009000400014>.